Charles Clausen recently posted on “The Prostate Problems Mailing List” the following about Transdermal Estradoil vs. LH-RH Agonists for Androgen Deprivation Therapy. I am planning to take a copy of this document with me to my next appointment with my Oncologist.
“Richard Wassersug, a biology professor (and Psychology from the Department of Anatomy and Neurobiology) at the Dalhousie U. medical
school in Halifax, recently presented a poster at the “Prostate
Cancer Conference 2007” in Toronto entitled “Transdermal Estradiol
versus LH-RH Agonists for Androgen Deprivation Therapy: Benefits and
Risks”. He sent me a PowerPoint presentation of this, accompanied by
an MS Word document listing references. I combined these in one
simplified PDF document, and have made it available for download at:” – (Charles Clausen)
Thank you Charles for your work combining the documents with the PowerPoint presentation and thank you Dr. Wassersug for the great poster presentation.
Dr. Wassersug is a prostate cancer survivor who has been on hormone therapy. He has written extensively and candidly about his experience. His publications about how he has experienced androgen deprivation have included one of the very best articles on deprivation I have ever read. This necessary read was published in the New York Times. It may be seen at “Disfiguring Treatment? No, It Was Healing”.
Joel T Nowak MA, MSW